Michael Gulrajani

1.2k total citations
18 papers, 662 citations indexed

About

Michael Gulrajani is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Michael Gulrajani has authored 18 papers receiving a total of 662 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Genetics, 9 papers in Pathology and Forensic Medicine and 5 papers in Immunology. Recurrent topics in Michael Gulrajani's work include Chronic Lymphocytic Leukemia Research (15 papers), Lymphoma Diagnosis and Treatment (9 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Michael Gulrajani is often cited by papers focused on Chronic Lymphocytic Leukemia Research (15 papers), Lymphoma Diagnosis and Treatment (9 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Michael Gulrajani collaborates with scholars based in United States, Denmark and Spain. Michael Gulrajani's co-authors include Todd Covey, Allard Kaptein, Raquel Izumi, Tjeerd Barf, Bas van de Kar, Fanny Krantz, Bart van Lith, Roger G. Ulrich, Dennis Demont and Diana Mittag and has published in prestigious journals such as Blood, PLoS ONE and Cancer Research.

In The Last Decade

Michael Gulrajani

17 papers receiving 651 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Gulrajani United States 8 542 408 206 162 159 18 662
Fanny Krantz United States 7 401 0.7× 300 0.7× 147 0.7× 129 0.8× 128 0.8× 12 495
Bart van Lith United States 7 319 0.6× 240 0.6× 131 0.6× 105 0.6× 87 0.5× 8 406
Елена Бибикова United States 9 326 0.6× 236 0.6× 153 0.7× 185 1.1× 141 0.9× 16 525
Kerstin Allen United States 13 467 0.9× 472 1.2× 116 0.6× 261 1.6× 248 1.6× 18 754
Thomas M. Jahn United States 11 636 1.2× 437 1.1× 204 1.0× 236 1.5× 219 1.4× 22 743
Sissy Peterman United States 14 1.1k 2.0× 806 2.0× 271 1.3× 434 2.7× 322 2.0× 16 1.3k
M Gorczyca United States 11 230 0.4× 217 0.5× 199 1.0× 173 1.1× 156 1.0× 33 565
Julia Schaefer-Cutillo United States 5 444 0.8× 419 1.0× 139 0.7× 148 0.9× 216 1.4× 6 664
Abdulraheem Yacoub United States 15 551 1.0× 159 0.4× 467 2.3× 366 2.3× 114 0.7× 122 917
Arnau Montraveta Spain 12 236 0.4× 182 0.4× 119 0.6× 281 1.7× 96 0.6× 17 492

Countries citing papers authored by Michael Gulrajani

Since Specialization
Citations

This map shows the geographic impact of Michael Gulrajani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Gulrajani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Gulrajani more than expected).

Fields of papers citing papers by Michael Gulrajani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Gulrajani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Gulrajani. The network helps show where Michael Gulrajani may publish in the future.

Co-authorship network of co-authors of Michael Gulrajani

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Gulrajani. A scholar is included among the top collaborators of Michael Gulrajani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Gulrajani. Michael Gulrajani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Gulrajani, Michael, Jean Cheung, Fanny Krantz, et al.. (2023). P1006: CHARACTERIZATION OF TL-895: A NOVEL BRUTON TYROSINE KINASE INHIBITOR (BTKI) IN CLINICAL DEVELOPMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MYELOFIBROSIS (MF). HemaSphere. 7(S3). e41702a0–e41702a0. 1 indexed citations
2.
Cheung, Jean, Fanny Krantz, Michael Gulrajani, et al.. (2023). P991: ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) POTENTIATES APOPTOSIS IN MYELOBLASTS FROM PATIENTS (PTS) WITH MYELOFIBROSIS (MF). HemaSphere. 7(S3). e281417f–e281417f.
3.
Elgamal, Sara, Michael Gulrajani, Jean Cheung, et al.. (2022). Elucidating the Mechanism of Action (MOA) of Navtemadlin, an MDM2 Inhibitor, and Its Synergy with Gilteritinib in Myeloid Malignancies. Blood. 140(Supplement 1). 5936–5938. 1 indexed citations
4.
Woyach, Jennifer A., James S. Blachly, Kerry A. Rogers, et al.. (2020). Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia. Cancer Discovery. 10(3). 394–405. 57 indexed citations
5.
Cheung, Jean, Michael Gulrajani, Erika M. Gaglione, et al.. (2020). Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib. Clinical Cancer Research. 26(12). 2800–2809. 21 indexed citations
6.
Bruin, Gerjan de, Dennis Demont, Edwin de Zwart, et al.. (2020). Discovery of quinoline-based irreversible BTK inhibitors. Bioorganic & Medicinal Chemistry Letters. 30(14). 127261–127261. 7 indexed citations
7.
Бибикова, Елена, Brian K. Law, Jean Cheung, et al.. (2019). High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL). Blood. 134(Supplement_1). 2571–2571. 1 indexed citations
8.
Kaptein, Allard, Gerjan de Bruin, Bas van de Kar, et al.. (2019). Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies. Clinical Lymphoma Myeloma & Leukemia. 19. S316–S317. 1 indexed citations
9.
Kaptein, Allard, Gerjan de Bruin, Bas van de Kar, et al.. (2018). Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies. Blood. 132(Supplement 1). 1871–1871. 71 indexed citations
10.
11.
Barf, Tjeerd, Todd Covey, Raquel Izumi, et al.. (2017). Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. Journal of Pharmacology and Experimental Therapeutics. 363(2). 240–252. 272 indexed citations
12.
Herman, Sarah E. M., Arnau Montraveta, Carsten Utoft Niemann, et al.. (2016). The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. Clinical Cancer Research. 23(11). 2831–2841. 121 indexed citations
13.
Harrington, Bonnie K., Heather L. Gardner, Raquel Izumi, et al.. (2016). Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. PLoS ONE. 11(7). e0159607–e0159607. 43 indexed citations
14.
Mora-Jensen, Helena, Carsten Utoft Niemann, Michael Gulrajani, et al.. (2016). Abstract 4797: The combination of ACP-196 and ACP-319 leads to increased survival in the TCL1-192 CLL mouse model. Cancer Research. 76(14_Supplement). 4797–4797. 1 indexed citations
15.
Covey, Todd, Tjeerd Barf, Michael Gulrajani, et al.. (2015). Abstract 2596: ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients. Cancer Research. 75(15_Supplement). 2596–2596. 36 indexed citations
16.
Herman, Sarah E. M., Arnau Montraveta, Carsten Utoft Niemann, et al.. (2015). The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia. Blood. 126(23). 2920–2920. 6 indexed citations
17.
Harrington, Bonnie K., Michael Gulrajani, Todd Covey, et al.. (2015). ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity. Blood. 126(23). 2908–2908. 17 indexed citations
18.
Covey, Todd, Manish Vira, Michael Gulrajani, et al.. (2013). Single cell network profiling assay in bladder cancer. Cytometry Part A. 83A(4). 386–395. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fanny Krantz Breakdown of academic impact, for papers by Bart van Lith Breakdown of academic impact, for papers by Елена Бибикова Breakdown of academic impact, for papers by Kerstin Allen Breakdown of academic impact, for papers by Thomas M. Jahn Breakdown of academic impact, for papers by Sissy Peterman Breakdown of academic impact, for papers by M Gorczyca Breakdown of academic impact, for papers by Julia Schaefer-Cutillo Breakdown of academic impact, for papers by Abdulraheem Yacoub Breakdown of academic impact, for papers by Arnau Montraveta
Rankless by CCL
2026